Adaptive Biotechnologies Lifts Forecasts

 Adaptive Biotechnologies reported a Q1 diluted loss per share of $0.20, an improvement from last year's $0.33 loss, surpassing analysts' expectations of a $0.29 loss. Revenue for Q1 hit $52.4 million, up from $41.9 million last year, beating the expected $42.7 million. Optimism is evident as full-year revenue guidance for its Minimal Residual Disease business was raised to between $180 million and $190 million. Additionally, the firm anticipates more efficient cash use, with a revised full-year cash burn forecast of $50 million to $60 million, lower than the previous $60 million to $70 million estimate.

https://finimize.com/content/adaptive-biotechnologies-lifts-forecasts-and-sees-share-price-jump